Report cover image

Cancer Immunotherapy Market Size, Share, By Product Type (Monoclonal Antibodies, Immunomodulators, Checkpoint Inhibitors, Adoptive Cell Therapy, and Others), Cancer Type (Lung Cancer, Colorectal Cancer, Melanoma, Breast Cancer, Head & Neck Cancer, Prostat

Publisher Prophecy Market Insights
Published Dec 01, 2024
Length 184 Pages
SKU # PRMI19511620

Description

Cancer immunotherapy represents a new and bright approach to cancer treatment, whereby one's immune system is manipulated to battle malignant cells. The increasing research in cancer immunotherapy is expected to propel market growth during the forecast period.

Cancer Immunotherapy Market Report Highlights:
  • The cancer immunotherapy market size is projected to reach USD 530.2 billion by 2034.
  • The market was valued at USD 158.5 billion in 2024.
  • The market is expected to expand at a CAGR of 14.2% during the forecast period.
  • North America holds the largest share in the market.
  • Asia Pacific is expected to witness fast growth during the forecast period.
  • By product type, the monoclonal antibodies segment is expected to lead the market during the forecast period.
  • On the basis of cancer type, lung cancer is the most dominant segment in the market.
  • Based on end-user, the market is being led by the hospitals segment.
Cancer Immunotherapy Market Key Highlights:
  • In June 2024, a new phase 2 research started to examine a triple medication combination for pancreatic cancer. The University of Glasgow and the NHS Greater Glasgow and Clyde have initiated a mid-stage trial to test a new drug combination as a first-line treatment for patients with metastatic pancreatic cancer. The phase 2 PRIMUS-006 study, part of the Precision-Panc Platform, will evaluate Eli Lilly and Genentech's Gemzar (gemcitabine) in combination with Merck & Co's Keytruda (pembrolizumab), known as MSD outside the U.S. and Canada, and Immodulon Therapeutics' investigational IMM-101 in metastatic pancreatic ductal adenocarcinoma (PDAC).
  • In April 2024, Hope beckons as the first homegrown cell therapy for cancer treatment is announced. President Droupadi Murmu introduced India's first indigenously developed CAR T-cell therapy for cancer treatment, calling it a "breakthrough" that will give humanity new hope in the fight against the disease. NexCAR19 CAR T-cell therapy is the country's first 'Made in India' cell therapy, and it will considerably reduce cancer treatment costs. This gene-based therapy, developed by the Indian Institute of Technology (IIT) Bombay and the Tata Memorial Centre, aims to cure several types of cancer.
Browse ∼37 market data tables and ∼39 figures through ∼167 slides and in-depth TOC on “Cancer Immunotherapy Market Size, Share, By Product Type (Monoclonal Antibodies, Immunomodulators, Checkpoint Inhibitors, Adoptive Cell Therapy, and Others), Cancer Type (Lung Cancer, Colorectal Cancer, Melanoma, Breast Cancer, Head & Neck Cancer, Prostate Cancer, and Others), End-User (Hospitals, Cancer Research Centers, and Others), and Region - Trends, Analysis and Forecast till 2034”

Cancer Immunotherapy Market Competitive Landscape:

The major players operating in the cancer immunotherapy market include Amgen, Inc., AstraZeneca, PLC, Bayer AG, Bristol-Myers Squibb Company, Eli Lily And Company, F. Hoffmann-La Roche, Ltd., Pfizer, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, and Immunocore, Ltd.

Segmentation:

By Product Type:
  • Monoclonal Antibodies
  • Immunomodulators
  • Checkpoint Inhibitors
  • Adoptive Cell Therapy
  • Others
By Cancer Type:
  • Lung Cancer
  • Colorectal Cancer
  • Melanoma
  • Breast Cancer
  • Head & Neck Cancer
  • Prostate Cancer
  • Others
By End-User:
  • Hospitals
  • Cancer Research Centers
  • Others
By Region:

North America
  • U.S.
  • Canada
Europe
  • Germany
  • U.K.
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

184 Pages
Research Objective and Assumption
Research Objectives
Assumptions
Abbreviations
Market Preview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Product Type
Market Snippet, By Cancer Type
Market Snippet, By End-User
Market Snippet, By Region
Opportunity Map Analysis
Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Market Trends
Product Launch
Merger and Acquisitions
Impact Analysis
PEST Analysis
Porter’s Analysis
Market Segmentation, By Product Type, Forecast Period up to 10 Years, (USD Bn)
Overview
Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
Segment Trends
Monoclonal Antibodies
Overview
Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
Immunomodulators
Overview
Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
Adoptive Cell Therapy
Overview
Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
Others
Overview
Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
Market Segmentation, By Cancer Type, Forecast Period up to 10 Years, (USD Bn)
Overview
Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
Segment Trends
Lung Cancer
Overview
Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
Colorectal Cancer
Overview
Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
Melanoma
Overview
Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
Breast Cancer
Overview
Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
Head & Neck Cancer
Overview
Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
Prostate Cancer
Overview
Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
Others
Overview
Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
Market Segmentation, By End-User, Forecast Period up to 10 Years, (USD Bn)
Overview
Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
Segment Trends
Hospitals
Overview
Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
Cancer Research Centers
Overview
Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
Others
Overview
Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
Market Segmentation, By Region, Forecast Period up to 10 Years, (USD Bn)
Overview
Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
Regional Trends
North America
Market Size and Forecast (USD Bn), By Product Type, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By Cancer Type, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By End-User, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
U.S
Canada
Asia Pacific
Market Size and Forecast (USD Bn), By Product Type, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By Cancer Type, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By End-User, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
India
Japan
South Korea
China
Rest of Asia Pacific
Europe
Market Size and Forecast (USD Bn), By Product Type, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By Cancer Type, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By End-User, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
UK
Germany
France
Russia
Italy
Rest of Europe
Latin America
Market Size and Forecast (USD Bn), By Product Type, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By Cancer Type, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By End-User, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
Brazil
Mexico
Rest of Latin America
Middle East and Africa
Market Size and Forecast (USD Bn), By Product Type, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By Cancer Type, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By End-User, Forecast Period up to 10 Years
Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
GCC
Israel
South Africa
Rest of Middle East and Africa
Competitive Landscape
Heat Map Analysis
Company Profiles
Amgen, Inc.
AstraZeneca, PLC
Bayer AG
Bristol-Myers Squibb Company
Eli Lily And Company
F. Hoffmann-La Roche, Ltd
Pfizer, Inc.
Johnson & Johnson Services, Inc
Merck & Co., Inc
Novartis AG
Immunocore, Ltd
The Last Word
Future Impact
About Us
Contact

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us